Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 10.00
Day High 10.00
Open:10.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidates consist of COG ACCL0431 and SIOPEL 6.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
GlobeNewswire - Mon Feb 4, 4:59AM CST
GlobeNewswire - CMTX
Mon Feb 4, 4:59AM CST
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate (STS) to be administered by infusion) for the prevention of ototoxicity induced by cisplatin chemotherapy in pediatric patients with solid tumors, announced a $12.5 million senior debt facility with the Life Sciences Group at Bridge Bank.
Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK(TM)
GlobeNewswire - Thu Dec 20, 5:00AM CST
GlobeNewswire - CMTX
Thu Dec 20, 5:00AM CST
-- PEDMARK is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors.
Today's Research Reports on Fennec Pharmaceuticals, Baylin Technologies, Canopy Growth and CardioComm Solutions
ACCESSWIRE - Tue Nov 27, 6:47AM CST
ACCESSWIRE - CMTX
Tue Nov 27, 6:47AM CST
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at and get exclusive access to our numerous research reports and market updates.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 8.42 +18.76% increase
on 01/30/19
Period Open:9.30
Price movement based on the high, low and last over the given period.
10.00 unch no change
on 02/20/19
+0.70 (+7.53%) increase
since 01/18/19
3-Month 7.22 +38.50% increase
on 12/19/18
Period Open:8.94
Price movement based on the high, low and last over the given period.
10.00 unch no change
on 02/20/19
+1.06 (+11.86%) increase
since 11/20/18
52-Week 7.22 +38.50% increase
on 12/19/18
Period Open:11.11
Price movement based on the high, low and last over the given period.
18.86 -46.98% decrease
on 04/09/18
-1.11 (-9.99%) decrease
since 02/16/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).